{"url_path":"/sec/spro/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221591-index.html","accession_number":"0001193125-26-221591","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221591-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":52,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDirector and Officer Trading Arrangements\n\nNone of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as such terms are defined in Items 408(a) and 408(c) of Regulation S-K, respectively) during the quarterly period covered by this report.\n\n80"}